The final rule (January 2017), which made revisions to the Department of Health and Human Services (HHS) human subject requirements (“Common Rule”), resulted in differences between HHS and FDA human subject regulations. FDA intends to revise its clinical investigation regulations to harmonize them with HHS. In the interim, the FDA has issued a new guidance for sponsors whose investigations must meet both FDA and HHS compliance requirements. (